Compare compounds

Sermorelin

Vials

5 / 10 mg

Dosing data

Lab reference — not listed

Tesamorelin

Vials

10 / 20 mg

Dosing data

Lab reference — not listed

Sermorelin

Sermorelin is the first 29 amino acids of GHRH, the shortest fully active fragment. It stimulates pituitary GHRH receptors to release GH.

Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl modification that improves stability against dipeptidyl peptidase-4 cleavage. It binds GHRH receptors on anterior pituitary somatotrophs, activating Gs/cAMP signaling to stimulate pulsatile endogenous growth hormone release, which in turn raises circulating IGF-1.

Sermorelin

• Used intravenously as a diagnostic test for GH deficiency, though a normal response cannot rule out hypothalamic causes.
• In some prepubertal children with idiopathic GH deficiency, height velocity increased significantly over 12 months, with limited data to 36 months.

Tesamorelin

• Reduced visceral adipose tissue (VAT) measured by CT in phase 3 trials in HIV-infected adults with abdominal fat accumulation.
• Increased IGF-1 levels while largely preserving physiological pulsatile GH secretion.
• Reduced hepatic fat fraction in HIV-associated fatty liver studies.
• VAT reductions were not maintained after treatment discontinuation in trial extension phases.

Sermorelin

• Was FDA-approved (Geref) but the branded product was discontinued; it is now mainly compounded or sold for research.
• Listed as prohibited in sport by the World Anti-Doping Agency.

Tesamorelin

• FDA-approved in 2010 (Egrifta) specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
• Label notes that long-term cardiovascular benefit and safety have not been established, and it is not indicated for weight loss.
• Use outside the approved indication is investigational.

Sermorelin

2 references · view

Tesamorelin

4 references · view